Get started
Work

Supplementary Figure 1 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Year: 2023
Type: supplementary-materials
Abstract: Outcomes for FLT3/ITD patients in the No-GO and GO cohorts who did not receive HCT. (A) RR and (B) DFS.
DOI: 10.1158/1078-0432.22460769
Authors: Katherine Tarlock, Todd A. Alonzo, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Lillian Sung, Jessica A. Pollard, Richard Aplenc, Michael R. Loken, Alan S. Gamis, Soheil Meshinchi
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362400023
Cites:
Cited by:
Related to: 10